TY - JOUR
T1 - The association of delta neutrophil index with the prognosis of acute exacerbation of chronic obstructive pulmonary disease
AU - Park, Sunmin
AU - Lee, Sang Jun
AU - Shin, Beomsu
AU - Lee, Seok Jeong
AU - Kim, Sang Ha
AU - Kwon, Woo Cheol
AU - Kim, Jihye
AU - Lee, Myoung Kyu
N1 - Publisher Copyright:
© 2020 The Author(s).
PY - 2020/2/19
Y1 - 2020/2/19
N2 - Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is associated with infective triggers including bacterial or viral in many cases, and pneumonia is a major contributor to hospitalization for AECOPD and has a close relationship with poor outcomes. Increased delta neutrophil index (DNI) can be useful in the detection of COPD patients with pneumonia. Methods: A retrospective cohort study was performed to investigate the mortality rate of the patients who were re-admitted within 6 months after discharge from the hospital due to AECOPD with or without CAP. We analyzed the difference of cumulative survival rate according to serum DNI level and readmission duration. Results: Finally, 140 AECOPD patients with community-acquired pneumonia (CAP) and 174 AECOPD patients without CAP were enrolled during 6 months, respectively. The mean age was 72.2 ± 9.4 year-old, and 240 patients (76.4%) were male. When comparing the cumulative survival rate according to readmission duration (≤ 30 vs > 30 days) and DNI level (< 3.5 vs ≥ 3.5%), AECOPD patients with readmission ≤30 days and DNI ≥ 3.5% showed the lowest cumulative survival rate compared to other groups (P < 0.001). Multivariate analysis revealed readmission duration ≤30 days (HR 7.879, 95% CI 4.554-13.632, P < 0.001); and serum DNI level (HR 1.086, 95% CI 1.043-1.131, P < 0.001) were significantly associated with the mortality of AECOPD patients during 6 months. The area under the curve for readmission (≤ 30 days) + DNI level (≥ 3.5%) was 0.753 (95% CI 0.676-0.830, P < 0.001) with a sensitivity of 73.7% and a specificity of 67.3%. Conclusion: AECOPD patients who were readmitted ≤30 days and DNI ≥ 3.5% showed higher mortality. DNI level can be used as a predictor of prognosis in AECOPD patients who were readmitted after discharge.
AB - Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is associated with infective triggers including bacterial or viral in many cases, and pneumonia is a major contributor to hospitalization for AECOPD and has a close relationship with poor outcomes. Increased delta neutrophil index (DNI) can be useful in the detection of COPD patients with pneumonia. Methods: A retrospective cohort study was performed to investigate the mortality rate of the patients who were re-admitted within 6 months after discharge from the hospital due to AECOPD with or without CAP. We analyzed the difference of cumulative survival rate according to serum DNI level and readmission duration. Results: Finally, 140 AECOPD patients with community-acquired pneumonia (CAP) and 174 AECOPD patients without CAP were enrolled during 6 months, respectively. The mean age was 72.2 ± 9.4 year-old, and 240 patients (76.4%) were male. When comparing the cumulative survival rate according to readmission duration (≤ 30 vs > 30 days) and DNI level (< 3.5 vs ≥ 3.5%), AECOPD patients with readmission ≤30 days and DNI ≥ 3.5% showed the lowest cumulative survival rate compared to other groups (P < 0.001). Multivariate analysis revealed readmission duration ≤30 days (HR 7.879, 95% CI 4.554-13.632, P < 0.001); and serum DNI level (HR 1.086, 95% CI 1.043-1.131, P < 0.001) were significantly associated with the mortality of AECOPD patients during 6 months. The area under the curve for readmission (≤ 30 days) + DNI level (≥ 3.5%) was 0.753 (95% CI 0.676-0.830, P < 0.001) with a sensitivity of 73.7% and a specificity of 67.3%. Conclusion: AECOPD patients who were readmitted ≤30 days and DNI ≥ 3.5% showed higher mortality. DNI level can be used as a predictor of prognosis in AECOPD patients who were readmitted after discharge.
UR - http://www.scopus.com/inward/record.url?scp=85079752072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079752072&partnerID=8YFLogxK
U2 - 10.1186/s12890-020-1083-4
DO - 10.1186/s12890-020-1083-4
M3 - Article
C2 - 32075629
AN - SCOPUS:85079752072
SN - 1471-2466
VL - 20
JO - BMC Pulmonary Medicine
JF - BMC Pulmonary Medicine
IS - 1
M1 - 47
ER -